Artiva Biotherapeutics, Inc. (ARTV) — Financial statements
Income statement, balance sheet, and cash flow for Artiva Biotherapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 0.25↓99.3% | 33↑579.2% | 5↑146.3% | 2 | |
| Cost of Revenue | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -3↓1134.7% | 0.25↓99.3% | 33↑579.2% | 5↑146.3% | 2 | |
| Operating Expenses | ||||||
| R&D Expenses | 70↑38.2% | 50↑0.2% | 50↑14.2% | 44↑3.7% | 42 | |
| General & Administrative Expenses | 20↑17.8% | 17↑23.7% | 14↓33.0% | 21↑61.5% | 13 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 20↑17.8% | 17↑23.7% | 14↓33.0% | 21↑61.5% | 13 | |
| Other Expenses | -2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 88↑30.3% | 68↑5.3% | 64↓0.9% | 65↑17.2% | 55 | |
| Total Costs & Expenses | 91↑34.2% | 68↑5.3% | 64↓0.9% | 65↑17.2% | 55 | |
| Operating Results | ||||||
| Operating Income | -91↓34.7% | -67↓119.4% | -31↑48.7% | -60↓12.3% | -53 | |
| Depreciation & Amortization | 3↑6.8% | 2↑7.3% | 2↑95.7% | 1↑366.9% | 0.25 | |
| EBITDA | -88↓35.7% | -65↓128.3% | -28↑51.6% | -59↑18.0% | -72 | |
| EBIT | -91↓34.7% | -67↓119.4% | -31↑48.7% | -60↑16.7% | -72 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↑11.4% | 5↑111.0% | 3↑95.9% | 1 | 0.00 | |
| Interest Income | 6↑11.4% | 5↑111.0% | 3↑95.9% | 1 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 19 | |
| Other Income / Expenses | 7↓23.3% | 9↑188.4% | 3↑103.9% | 1↑108.1% | -19 | |
| Income Before Tax | -84↓43.4% | -58↓111.7% | -28↑52.6% | -58↑18.8% | -72 | |
| Income Tax Expense | 0.00 | 0.00↓100.0% | 0.07↑35.8% | 0.05 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -84↓43.4% | -58↓111.2% | -28↑52.6% | -58↑18.7% | -72 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -84↓43.4% | -58↓111.2% | -28↑52.6% | -58↑18.7% | -72 | |
| Bottom-Line Net Income | -84↓43.4% | -58↓111.2% | -28↑52.6% | -58↑18.7% | -72 | |
| EPS (Basic) | -3.43↑34.0% | -5.20↓337.0% | -1.19↑64.2% | -3.32↑18.6% | -4.08 | |
| EPS (Diluted) | -3.43↑34.0% | -5.20↓337.0% | -1.19↑64.2% | -3.32↑18.6% | -4.08 | |
| Weighted Average Shares | 24↑0.3% | 24↑4.6% | 23↑32.4% | 18↑0.0% | 18 | |
| Weighted Average Diluted Shares | 24↑0.3% | 24↑4.6% | 23↑32.4% | 18↑0.0% | 18 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.